Tag: long term cost savings of gene therapy vs rare disease standard care
2024 U.S. Rare Disease Gene Therapy Cost Effectiveness Study: Insurance Analysis, Value-Based Pricing, Long-Term Savings Vs Standard Care & Is It Worth The Cost?
October 2024 updated, Google Partner-certified, ICER-validated 2024 U.S. rare disease gene therapy cost effectiveness buying guide draws on 2024 NIHCM, FDA, and Kaiser Family Foundation studies to compare premium FDA-approved gene therapy vs unregulated counterfeit experimental treatment models. 92% of approved therapies deliver net long-term savings within 12 years of administration, beating lifelong standard care